GlycoNex Incorporation

NT$19.95As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4168Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (5.10%)
Div yield —
ROE (29.27%)
Biotechnology
Beta (5Y) 0.60
PE TTM —
TSR TTM (13.26%)
Mkt cap NT$2.245B
ROIC (16.03%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$20
(1.30%)
(46.74%)
Hold 5|5|7|1|10
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.30
0.33
0.32
0.33
(2.21%)
14.08%
11.39%
8.47%
RevenueNT$M
195.2
191.0
189.7
196.0
1.79%
(2.80%)
(2.03%)
0.54%
Peers (US$67.80M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.302
(0.563)
(0.509)
EBIT/Intx
7.778
0.532
0.627
Own earn%
(34.41)
124.98
112.41
Sh yield%
27.61
35.44
32.01
Owners
Insiders/Inst%
6.40
49.03
Short interest%
1.13
SBC / revenue%
3.04
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
9–15
$1 testx
0.9
Incr. ROIC%
1